Prelude Therapeutics Incorporated (PRLD) Stock

Prelude Therapeutics Incorporated (PRLD) is a Healthcare stock trading at $4.32 (as of 2026-06-18), with a market capitalization of $312.21M and a trailing P/E of -3.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company developing targeted cancer therapies for solid tumors and myeloid malignancies. Its pipeline includes PRT543 and PRT811 in Phase 1 trials, along with earlier-stage programs such as PRT1419 and other precision oncology candidates.

Valuation — source: SEC EDGAR (first-party)
Price	$4.32
Market Cap	$312.21M
P/E Ratio	-3.9
EV / EBITDA	-3.5
Price / Book	5.19
Price / Sales	18.67
DCF Value (model)	$-14.62
DCF Upside vs Price	-438.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$12.14M
Net Margin	-819.6%
Return on Equity	-129.3%
Current Ratio	2.03
Revenue Growth (YoY)	73.4%
EPS Growth (YoY)	-23.2%
FCF Growth (YoY)	-45.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-6.43 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-118.8%
vs Industry	-123.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	ORBIMED ADVISORS LLC ($37.31M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Krishna Vaddi
Employees	131
Country	US
IPO Date	2020-09-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.